{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-001416","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2024-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.768041+00:00","generated_at":"2026-06-07T01:30:12.288440+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Elicio reports Phase 1 data for ELI-002: 84% T cell response, 16.3-month median RFS","bullets":["AMPLIFY-201 data published in Nature Medicine in 25 patients (20 pancreatic, 5 colorectal) with minimal residual mKRAS disease.","ELI-002 induced direct ex vivo mKRAS-specific T cell responses in 84% of patients; 59% both CD4+ and CD8+.","84% of patients had tumor biomarker reduction; 24% achieved complete biomarker clearance.","Median relapse-free survival was 16.33 months; high T cell responders had 86% reduction in risk of progression or death.","Phase 2 monotherapy trial in pancreatic ductal adenocarcinoma planned to start early 2024; no safety concerns identified."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-001416","json":"https://secwatch.observer/filing/0001140361-24-001416.json","markdown":"https://secwatch.observer/filing/0001140361-24-001416.md","text":"https://secwatch.observer/filing/0001140361-24-001416.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000114036124001416/0001140361-24-001416-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000114036124001416/ef20018418_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:30:12.288440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}